Article
Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study
Affiliations
Organisations
- (1) University of Queensland, grid.1003.2
- (2) QIMR Berghofer Medical Research Institute, grid.1049.c
- (3) Baylor College of Medicine, grid.39382.33
- (4) University of Cambridge, grid.5335.0
- (5) University of Michigan, grid.214458.e
- (6) University of Southern California, grid.42505.36
- (7) Vanderbilt University, grid.152326.1
- (8) Peter MacCallum Cancer Centre, grid.1055.1
- (9) University of California, Los Angeles, grid.19006.3e
- (10) Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Universitätsstrasse 21-23, 91054, Erlangen, Germany
- (11) Flanders Institute for Biotechnology, grid.11486.3a
- (12) KU Leuven, grid.5596.f
- (13) Universitair Ziekenhuis Leuven, grid.410569.f
- (14) University of Washington, grid.34477.33
- (15) Fred Hutchinson Cancer Research Center, grid.270240.3
- (16) Dartmouth College, grid.254880.3
- (17) University Cancer Center Hamburg, grid.412315.0
- (18) German Cancer Research Center, grid.7497.d
- (19) Roswell Park Cancer Institute, grid.240614.5
- (20) Cedars-Sinai Medical Center, grid.50956.3f
- (21) University of Hawaii at Manoa, grid.410445.0
- (22) Hannover Medical School, grid.10423.34
- (23) Department of Pathology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00029, Helsinki, Finland
- (24) Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 8, 00029, Helsinki, Finland
- (25) Ovarian Cancer Center of Excellence, Women’s Cancer Research Program, Magee-Women’s Research Institute and University of Pittsburgh Cancer Institute, 204 Craft Avenue, 15213, Pittsburgh, PA, USA
- (26) University of Pittsburgh, grid.21925.3d
- (27) The University of Texas Health Science Center at Houston, grid.267308.8
- (28) Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Ludwig-Erhard-Strasse 100, 65199, Wiesbaden, Germany
- (29) Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/ Knappschaft GmbH, Henricistrasse 92, 45136, Essen, Germany
- (30) Praxis für Humangenetik, grid.461735.2
- (31) Danish Cancer Society, grid.417390.8
- (32) Department of Gynaecology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100, Copenhagen, Denmark
- (33) Herlev Hospital, grid.411900.d, Capital Region
- (34) Department of Health Science Research, Division of Epidemiology, Mayo Clinic, 200 First Street SW, Charlton 6, 55905, Rochester, MN, USA
- (35) Moffitt Cancer Center, grid.468198.a
- (36) Mayo Clinic, grid.66875.3a
- (37) Division of Biomedical Statistics and Informatics, Department of Health Science Research, Mayo Clinic, 200 First Street SW, Charlton 6, 55905, Rochester, MN, USA
- (38) Monash University, grid.1002.3
- (39) Cancer Council Victoria, grid.3263.4
- (40) University of Melbourne, grid.1008.9
- (41) The University of Texas MD Anderson Cancer Center, grid.240145.6
- (42) Texas Southern University, grid.264771.1
- (43) New York University Langone Medical Center, grid.240324.3
- (44) Memorial Sloan Kettering Cancer Center, grid.51462.34
- (45) University of Virginia, grid.27755.32
- (46) Duke University Hospital, grid.189509.c
- (47) Brigham and Women's Hospital, grid.62560.37
- (48) Harvard University, grid.38142.3c
- (49) Rutgers, The State University of New Jersey, grid.430387.b
- (50) Haukeland University Hospital, grid.412008.f
- (51) University of Bergen, grid.7914.b
- (52) Radboud University Nijmegen Medical Centre, grid.10417.33
- (53) Oregon Health & Science University, grid.5288.7
- (54) University of New Mexico, grid.266832.b
- (55) BC Cancer Agency, grid.248762.d
- (56) University of British Columbia, grid.17091.3e
- (57) Simon Fraser University, grid.61971.38
- (58) Medical University of South Carolina, grid.259828.c
- (59) Pomeranian Medical University, grid.107950.a
- (60) National Cancer Institute, grid.48336.3a
- (61) Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, grid.418165.f
- (62) University of Southampton, grid.5491.9
- (63) University of Glasgow, grid.8756.c
- (64) Beatson West of Scotland Cancer Centre, grid.422301.6
- (65) Glasgow Royal Infirmary, grid.411714.6
- (66) Stanford University, grid.168010.e
- (67) Icahn School of Medicine at Mount Sinai, grid.59734.3c
- (68) University of Toronto, grid.17063.33
- (69) Yale University, grid.47100.32
- (70) Public Health Ontario, grid.415400.4
- (71) University of California, Irvine, grid.266093.8
- (72) University College London, grid.83440.3b
- (73) Center for Cancer Prevention and Translational Genomics, Samuel Oschin Cancer Institute, Spielberg Building, 8725 Alden Dr., 90048, Los Angeles, CA, USA
- (74) Garvan Institute of Medical Research, grid.415306.5
- (75) School of Women’s and Children’s Health, University of New South Wales, Level 1, Women’s Health Institute, Royal Hospital for Women, Barker Street, 2031, Randwick, NSW, Australia
Countries
Continents
Description
BACKGROUND: Observational studies suggest greater height is associated with increased ovarian cancer risk, but cannot exclude bias and/or confounding as explanations for this. Mendelian randomisation (MR) can provide evidence which may be less prone to bias. METHODS: We pooled data from 39 Ovarian Cancer Association Consortium studies (16,395 cases; 23,003 controls). We applied two-stage predictor-substitution MR, using a weighted genetic risk score combining 609 single-nucleotide polymorphisms. Study-specific odds ratios (OR) and 95% confidence intervals (CI) for the association between genetically predicted height and risk were pooled using random-effects meta-analysis. RESULTS: Greater genetically predicted height was associated with increased ovarian cancer risk overall (pooled-OR (pOR) = 1.06; 95% CI: 1.01-1.11 per 5 cm increase in height), and separately for invasive (pOR = 1.06; 95% CI: 1.01-1.11) and borderline (pOR = 1.15; 95% CI: 1.02-1.29) tumours. CONCLUSIONS: Women with a genetic propensity to being taller have increased risk of ovarian cancer. This suggests genes influencing height are involved in pathways promoting ovarian carcinogenesis.
Funders
Research Categories
Main Subject Area
Fields of Research